Who is sponsoring NCT03472053?

NCT03472053 is sponsored by BioMarck Pharmaceuticals, Ltd..

What drugs are being tested in NCT03472053?

Interventions in NCT03472053: BIO-11006 plus standard of care, Standard of Care.

What condition does NCT03472053 study?

NCT03472053 studies Non Small Cell Lung Cancer Stage IIIB.

Is NCT03472053 still recruiting?

NCT03472053 is currently completed. Last updated 19 May 2020.

Last reviewed 2020-05-19 · How we verify

NCT03472053

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer

Completed Phase 2 Last updated 19 May 2020

What this trial tests

Phase 2 trial testing BIO-11006 plus standard of care in Non Small Cell Lung Cancer Stage IIIB in 60 participants. Completed in 30 December 2019.

Timeline

1 February 2018

Primary endpoint
30 December 2019

30 December 2019

Quick facts

Lead sponsor	BioMarck Pharmaceuticals, Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 February 2018
Primary completion	30 December 2019
Estimated completion	30 December 2019
Sites	11 locations across India

Drugs / interventions tested

BIO-11006 plus standard of care — full drug profile →
Standard of Care

Conditions studied

Non Small Cell Lung Cancer Stage IIIB — all drugs for Non Small Cell Lung Cancer Stage IIIB →

Sponsor

BioMarck Pharmaceuticals, Ltd. — full company profile →

Who can join

Adults 18 to 70, any sex, with Non Small Cell Lung Cancer Stage IIIB. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 2 is a randomized study in advanced Non-Small Cell lung cancer patients to evaluate safety and efficacy of aerosolized BIO-11006 in conjunction with chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

MARCKS and Lung Disease.
Sheats MK, Yin Q, Fang S, Park J, et al · · 2019 · cited 24× · PMID 30339463 · DOI 10.1165/rcmb.2018-0285tr

Verify or expand the search:

Other BioMarck Pharmaceuticals, Ltd. trials

Trials by the same sponsor.

NCT03202394 — Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03472053 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioMarck Pharmaceuticals, Ltd.
Last refreshed: 19 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03472053.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing